Mayo Clinic Foundation

AI and advanced analytics tools can streamline healthcare organizations’ clinical and non-clinical workflows, allowing clinicians and staff to focus on higher-value tasks. However, thoughtful implementation and change management is crucial for adoption of these tools. In season 2, episode 5 of the "Unlocking Big Data" podcast sponsored by Arcadia, John Halamka, Mayo Clinic Platform president, and Arcadia president and CEO Michael Meucci, talk about important steps healthcare organizations should take to ensure that any AI tools they use deliver accurate results and help increase equitable care delivery. You'll learn about: How healthcare leaders can set their organizations up for successful AI deployment Data analytics platforms’ role in optimizing resource management and personalizing patient care The most impactful use cases for data analytics and AI tools Want to hear more about this topic? Watch our companion TV episode here .

Mayo Clinic on Wednesday welcomed seven more healthcare startups to its accelerator program to help young companies develop and validate their artificial intelligence-powered healthcare products. The announcement came just months after Mayo Clinic selected the program’s initial cohort of four companies in March. Each company participating in the 20-week program, called Mayo Clinic Platform_Accelerate, receives a $200,000-benefit package. As a condition of this investment, Mayo Clinic Platform receives an equity position in each startup. The package allows startups to refine their AI models using Mayo Clinic’s deidentified data sets and get feedback from Mayo Clinic’s subject matter experts, including clinicians, researchers and product development professionals. It also gives startups the opportunity to attend workshops and presentations about topics ranging from FDA clearance requirements to AI ethics. Some of these workshops are led by experts from Google and Epic, according to Eric Harnisch, Mayo Clinic Platform’s vice president of partner programs. The companies chosen for the program’s second cohort went through a selection process in which Mayo Clinic experts assessed their potential to address unmet medical needs with the use of AI. Harnisch said the team selected companies that had robust data science foundation and prior experience with Google Cloud Platform, as that is Mayo Clinic’s cloud provider. Here are the seven startups selected: AESOP Technology Berkeley, California-based AESOP, which stands for AI-Enhanced Safety of Prescription, develops automation software to improve the clinical decision support process and make physician data entry faster and less error-prone. It recently launched its latest clinical documentation improvement tool, which helps medical coders flag diagnoses or procedures that were flagged incorrectly. The startup has offices in California, Colorado and Taiwan. Biotia New York City-based Biotia is a spinout of Cornell Tech that is focused on battling infectious diseases with AI and genomics. The company claims it is working toward developing the world’s leading microbial sequence database. It is currently creating DNA sequencing technology to allow for the personalized discovery of disease-causing microorganisms. This rapid precision infectious disease discovery would guide better patient treatment and improve health outcomes, according to the startup. Delfina San Francisco-based Delfina is a maternal telehealth company that remotely monitors pregnant women to assess health risks and collaborates with providers to produce a personalized care plan. The startup partners with OBGYN providers to offer its services to their patients in an effort to lower the country’s maternal mortality rate, which is the highest among all developed nations. The company also has offices in New York City and Rochester, Minnesota. Dynocardia Cambridge, Massachusetts-based Dynocardia uses wearable technology to track real-world continuous blood pressure and other advanced heart function measures. It created ViTrack, a cuff-less wearable that enables non-invasive blood pressure measurement and leverages AI for the early detection of heart issues to prevent serious health events. ImpriMed Palo Alto-based ImpriMed is aiming to validate a personalized medicine platform for human and animal cancer patients. Using AI, the startup’s platform gives patients and clinicians predictive information for personalized cancer treatment pathways, allowing oncologists to quickly identify which available drugs provide the best clinical outcomes for a particular patient. The company also has offices in Seoul. Predicta Med Tel Aviv-based Predicta Med offers an AI-powered decision support platform for the early detection of autoimmune diseases. Using EMRs and claims data, the company built algorithms that detect various autoimmune diseases. The startup’s platform shows clinicians which patients are at risk and provides treatment recommendations. It believes that early detection and intervention decreases health plans’ costs and strengthens treatment efficacy. SOAP Health Boca Raton-based SOAP Health stands for Subjective, Objective, Assessment, Plan. Its software is designed to improve early disease detection and diagnosis at the point of care. The startup offers an EHR-integrated platform with a patient and physician-facing interface that is powered by conversational AI. This platform identifies at-risk patients who meet national medical associations’ guidelines for increased surveillance for cancer, heart disease and type 2 diabetes.

Mayo Clinic on Wednesday announced the launch of a new platform that's designed to deliver advanced, AI-powered clinical decision support through remote monitoring. It helps providers stay connected and deliver more continuous care to device-connected patients. WHY IT MATTERS The health system's new Remote Diagnostics and Management Platform was created to deliver what it calls "event-driven medicine," connecting patient data with machine learning algorithms within existing clinical workflows and enabling care in the "right context, at the right time." "The dramatically increased use of remote patient telemetry devices, coupled with the rapidly accelerating development of AI and machine learning algorithms, has the potential to revolutionize diagnostic medicine," said Mayo Clinic Platform president Dr. John Halamka in a statement. "With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings," he added. "The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them." To help the new platform capitalize on its potential, Mayo Clinic worked with vendor partners to launch two new spinoff companies, each focused on a specific aspect of that AI-powered connected health. Anumana, created in collaboration with biomedical-data company nference, is focused on commercialization of AI-enabled algorithms and bringing digital sensor diagnostics to market. Its first goal is to improve early detection and treatment of heart disease by designing new neural-network algorithms based on troves of heart health data in Mayo's Clinical Data Analytics Platform, including raw ECG signals. Lucem Health, meanwhile, is designed to "collect, orchestrate and curate data from any device," according to Mayo Clinic. Launched with doctor-focused developer startup Commure, Lucem will provide the overall platform for connecting remote-telemetry devices with the algorithms developed by Anumana and Mayo, and will be responsible for integrating those AI-powered diagnostic insights into clinical workflows. Anumana completed $25.7 million in Series A financing, led by founders nference and Mayo Clinic, along with Matrix Capital Management, Matrix Partners and NTTVC, as part of this initiative. Lucem Health completed $6 million in Series A, led by Mayo and Commure. "When technology and policy and culture align, you see radical change and innovation," said Halamka during a teleconference announcing the RDMP launch. "Think for a moment what we've seen over this last year of COVID-19. We see that all of us are carrying these super-computing devices. Many of us have wearable devices. In fact, our homes may be smart and have sensors. "So here's the interesting quandary," he said. "If you, as a primary care provider or specialist, want to work with a patient, if you were the payer or pharma or government and you want to ensure the health and wellbeing of a population, how do you take all this new data that is coming from the devices we have, and wear, and are in our homes around us, and turn it into wisdom? How do you respond to events rapidly? How do you filter the signal from the noise? "What's happening in 2021 is we are seeing the emergence of sophisticated AI algorithms that can, in combination with novel data sources, result in breakthroughs in disease detection and wellness," he added. "But that will require an assembly of technology, policy and patient engagement, combined with cultural change in order to make it happen." THE LARGER TREND "Undiagnosed heart disease affects millions of Americans, and people across the globe," said Dr. Paul Friedman, chair of the Department of Cardiovascular Medicine at Mayo Clinic. "For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, effective evidence-based treatments exist that can prevent heart failure, stroke or death. The key is to detect the disease before symptoms develop to prevent these events from happening. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated into medical workflows, makes this approach good for patients, convenient for clinicians and massively scalable." ON THE RECORD "ECGs have been read and notated manually by physicians for more than a century," said Murali Aravamudan, cofounder and CEO of nference and CEO of Anumana, in a statement. "Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a comprehensive translation of the language of the heart. We think of it as the Rosetta Stone for cardiac medicine." "Lucem Health exists to help diagnostic medicine innovations see the light of day," said Sean Cassidy, founding CEO of Lucem Health. "We are excited to work with partners like Mayo Clinic and Anumana that are reimagining how we detect and treat diseases."